Evaluation of cytotoxic effects of several novel tetralin derivatives against Hela, MDA-MB-468, and MCF-7 cancer cells

Shafiee, Fateme; Sadeghi-aliabadi, Hojjat; Hassanzadeh, Farshid

Evaluation of cytotoxic effects of several novel tetralin derivatives against Hela, MDA-MB-468, and MCF-7 cancer cells

Authors

¹ Department of Pharmaceutical Chemistry, Isfahan University of Medical Sciences, Isfahan, Iran

² Department of Pharmaceutical Chemistry, Isfahan University of Medical Sciences, Isfahan; Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: The inhibitors of the enzymes estrone sulfatase and 17-β-hydroxysteroid dehydrogenase (17-β-HSD) could provide a means of blocking estrogen biosynthesis leading to regression of estrogen-dependent tumors. We evaluated the cytotoxicity of several tetralin derivatives, 2-(4-halo-phenylmethylene)-3,4-dihydronaphthalene-1-ones, as potential inhibitors of these two enzymes, on Hela, MDA-MB-468, and MCF-7 cancer cell lines.
Materials and Methods: The cell lines were cultured in RPMI medium and the cytotoxic effect of tested compounds (compounds 1 to 5) was screened at the concentrations of 0.1, 1, and 10 μM either alone or in combination with doxorubicin (100 μM), using MTT assay. The mixtures of cell suspension with solvent (1% DMSO in PBS) and doxorubicin (100 μM) were used as negative and positive controls, respectively. Each concentration of compounds was assayed in four wells and repeated in at least three independent experiments for each cell line. The cytotoxic effect of each particular concentration of tested compounds was expressed as the percent of cell survival.
Results: None of the compounds exhibited cytotoxic effect (reduction of cell survival to less than 50%) on tested cell lines. However, statistically significant reduction in cell survival was observed for some compounds against particular cell lines. Among all tested combinations of compounds with doxorubicin against cell lines, only compound 4 at 10 μM concentration showed synergistic cytotoxic effect with doxorubicin against Hela cells.
Conclusion: With the exception of compound 2, other tested compounds have potential for further cytotoxicity evaluation. Synthesizing other tetralin derivatives similar to compound 4 and studying their structure-activity relationships (SARs) would be encouraged.

Keywords

References

1.	Ma DD, Bell DR. Multidrug resistance and P-glycoprotein expression in human cancer. Aust NZ J Med 1989;19:736-43. [PUBMED]
2.	Group EBCTC. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-67.
3.	Lazarus P, Blevins-Primeau AS, Zheng Y, Sun D. Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen. Ann N Y Acad Sci 2009;1155:99-111. [PUBMED]
4.	Prost O, Turrel MO, Dahan N, Craveur C, Adessi GL. Estrone and dehydroepiandrosterone sulfatase activities and plasma estrone sulfate levels in human breast carcinoma. Cancer Res 1984;44:661-4. [PUBMED]
5.	Selcer KW, Jagannathan S, Li PK. Inhibition of placental estrone sulfatase activity and MCF-7 breast cancer cell proliferation by estrone-3-amino derivatives. J Steroid Biochem Mol Biol 1996;59:83-91. [PUBMED]
6.	Santer SJ, Feil PD, Santen RJ. In situ oestrogen production via oestrone sulphatase pathway in breast tumours: Relative importance versus the aromatase pathway. J Clin Endocrinol Metab 1984;59:29-33.
7.	Saito T, Kinoshita S, Fujii T, Bandoh K, Fuse S, Yamauchi Y, et al. Development of novel steroid sulfatase inhibitors: II. TZS-8478 potently inhibits the growth of breast tumors in postmenopausal breast cancer model rats. J Steroid Biochem Mol Biol 2004;88:167-73. [PUBMED]
8.	Reed MJ, Purohit A. Sulphatase inhibitors: The rationale for the development of a new endocrine therapy. Rev Endocrine-Related Cancer 1993;45:51-62.
9.	Reed MJ, Lai LC, Owen AM, Singh A, Coldham NG, Purohit A, et al. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer. Cancer Res 1990;50:193-6. [PUBMED]
10.	Mehta RR, Das Gupta TK. Regulation of 17 beta-hydroxysteroid dehydrogenase in a newly-established human breast carcinoma cell line. J Steroid Biochem Mol Biol 1993;46:623-9. [PUBMED]
11.	Hassanzadeh F. Design and synthesis of inhibitors of steroid sulphatase and 17-beta-hydroxysteroid dehydrogenase as potential agents in the treatment of breast cancer. PhD Thesis. Cardiff, UK: University of Wales; 1996.
12.	Li PK, Chu GH, Guo JP, Peters A, Selcer KW. Development of potent non-estrogenic estrone sulfatase inhibitors. Steroids 1998;63:425-32. [PUBMED]
13.	Taguchi Y, Koslowski M, Bodenner DL. Binding of estrogen receptor with estrogen conjugated to bovine serum albumin (BSA). Nucl Recept 2004;2:5. [PUBMED]
14.	Selcer KW, Hegde PV, Li PK. Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-o-sulfamoyl)-N-alkanoyl tyramines. Cancer Res 1997;57:702-7. [PUBMED]
15.	Laplante Y, Cadot C, Fournier MA, Poirier D. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Blocking of ER+ breast cancer cell proliferation induced by estrone. Bioorg Med Chem 2008;16:1849-
16.	Li S, Zhou Y, Wang R, Zhang H, Dong Y, Ip C. Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Ther 2007;6:1031-
17.	Hu Y, Krishan A, Nie W, Sridhar KS, Mayer LD, Bally M. Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells. Clin Cancer Res 2004;10:1160-9. [PUBMED]

Advanced Biomedical Research